Patent US10603301

Cannabis-based extracts and topical formulations for use in skin disorders
[+] Show Details

US10603301

1. A method of treating or inhibiting an inflammatory skin disease in a human in need thereof comprising topically administering to the human a therapeutically effective amount of a pharmaceutical composition comprising: (11) (2)

a. a carrier formulation comprising β-caryophyllene, salicylic acid, and at least at least one of: i. glycerin; or

ii. niacinamide; and

b. cannabis oil comprising cannabidiol and tetrahydrocannabinol, wherein the inflammatory skin disease is selected from the group consisting of spongiotic dermatitides, psoriasiform dermatitides, interface dermatitides, bullous disease, dermatitides with perivascular inflammation, vasculitis, nodular and diffuse dermatitides, seborrheic dermatitis, lupus erythematosus, discoid lupus erythematosus, dermatomyositis, lichen planus, lichen sclerosus, lichen simplex chronicus, psoriasis, lichen striatus, lichen aureus, granuloma faciale, atopic dermatitis, sweet syndrome, granuloma inguinale, pyoderma gangrenosum, necrobiotic xanthogranuloma, pemphigus, pemphigus foliaceus, pemphigus vulgaris, dermatitis herpetiformis, erythema multiforme, follicular occlusion triad, ruptured cyst/follicle, cutaneous T-cells lymphoma, poison ivy, nummular dermatitis, and eczema.

2. The method of claim 1, wherein the cannabidiol:tetrahydrocannabinol concentrations ratio in the cannabis oil is 1%:1%, 3%:1%, 1%:3%, or 3%:3% by weight. (0)

3. The method of claim 1, wherein the pharmaceutical composition comprises: (0) (2)

4. The method of claim 1, wherein the concentration of cannabidiol and tetrahydrocannabinol each is 3% by weight, and the concentration of said β-caryophyllene is 0.5% by weight. (0)

5. The method of claim 1, wherein the topically administered pharmaceutical composition provides a synergistic effect with respect to treatment of the inflammatory skin disease as compared to the effect provided by administering the carrier formulation or the cannabis oil, each alone. (1) (0)

9. The method of claim 1, wherein the topically administered pharmaceutical composition provides a synergistic effect with respect to reduction of hyperproliferation, reduction of IL-8 secretion, reduction of IL-33 secretion, reduction of skin inflammation, reduction of epidermal turnover rate, and any combination thereof, as compared to the effect provided by administering the carrier formulation or the cannabis oil, each alone. (0)

10. The method of claim 1, wherein the topically administered pharmaceutical composition provides a synergistic effect with respect to inhibition of skin hyperproliferation and skin inflammation as compared to the effect provided by each component of the carrier formulation (a) when administered separately in a similar concentration. (0)

11. The method of claim 1, wherein the pharmaceutical composition is formulated in a dosage form selected from the group consisting of cream, ointment, lotion, foam, film, transdermal patch and any combination thereof. (0)

12. The method of claim 1, further comprising administration of at least one additional therapeutic agent selected from the group consisting of methotrexate, cyclosporine, hydroxycarbamide, fumarates, retinoids, efalizumab and alefacept, vitamin D and derivatives thereof, and any combination thereof. (1) (0)

14. The method of claim 1, wherein the pharmaceutical composition is formulated for administration in a therapeutic dosage selected from the group consisting of: (0) (6)

a. a dosage of up to about 1500 mg per day;

b. a dosage in the range of from about 100 mg to about 1500 mg per day;

c. a dosage comprising an amount of up to about 30 mg each of cannabidiol or tetrahydrocannabinol or both, and an amount of up to about 5 mg β-caryophyllene, administered once, twice or thrice daily;

d. a dosage comprising an amount of cannabidiol of up to about 30 mg per day, about up to 100 mg per day, or in the range of from about 10 mg to about 100 mg per day;

e. a dosage comprising an amount of tetrahydrocannabinol of up to about 30 mg per day, about up to 100 mg per day, or in the range of from about 10 mg to about 100 mg per day; and

f. a dosage comprising an amount of β-caryophyllene of up to about 5 mg per day, up to about 100 mg per day, or in the range of from about 3 mg to about 10 mg per day.

15. The method of claim 1, wherein the amount of cannabis oil in the pharmaceutical composition is about 10% by weight. (0)

16. The method of claim 1, wherein the inflammatory skin disease is psoriasis. (1) (0)

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Patent US10603301

Cannabis-based extracts and topical formulations for use in skin disorders

Patent Matrix® Search